JPWO2021064428A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021064428A5 JPWO2021064428A5 JP2022520570A JP2022520570A JPWO2021064428A5 JP WO2021064428 A5 JPWO2021064428 A5 JP WO2021064428A5 JP 2022520570 A JP2022520570 A JP 2022520570A JP 2022520570 A JP2022520570 A JP 2022520570A JP WO2021064428 A5 JPWO2021064428 A5 JP WO2021064428A5
- Authority
- JP
- Japan
- Prior art keywords
- bicyclic peptide
- heterotandem
- conjugate according
- peptide conjugate
- heterotandem bicyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000002619 bicyclic group Chemical group 0.000 description 29
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 239000000863 peptide conjugate Substances 0.000 description 18
- 239000003446 ligand Substances 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 239000002062 molecular scaffold Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 108010055196 EphA2 Receptor Proteins 0.000 description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 102100035486 Nectin-4 Human genes 0.000 description 2
- 101710043865 Nectin-4 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- PECGVEGMRUZOML-AWEZNQCLSA-N (2s)-2-amino-3,3-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C([C@H](N)C(O)=O)C1=CC=CC=C1 PECGVEGMRUZOML-AWEZNQCLSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- SRGOJUDAJKUDAZ-LURJTMIESA-N (2s)-2-amino-3-cyclobutylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1CCC1 SRGOJUDAJKUDAZ-LURJTMIESA-N 0.000 description 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OYIFNHCXNCRBQI-BYPYZUCNSA-N L-2-aminoadipic acid Chemical compound OC(=O)[C@@H](N)CCCC(O)=O OYIFNHCXNCRBQI-BYPYZUCNSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025101880A JP7770607B2 (ja) | 2019-10-03 | 2025-06-18 | ヘテロタンデム二環式ペプチド複合体 |
| JP2025185492A JP2026027327A (ja) | 2019-10-03 | 2025-11-04 | ヘテロタンデム二環式ペプチド複合体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910129P | 2019-10-03 | 2019-10-03 | |
| US62/910,129 | 2019-10-03 | ||
| PCT/GB2020/052445 WO2021064428A1 (en) | 2019-10-03 | 2020-10-05 | Heterotandem bicyclic peptide complexes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101880A Division JP7770607B2 (ja) | 2019-10-03 | 2025-06-18 | ヘテロタンデム二環式ペプチド複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551607A JP2022551607A (ja) | 2022-12-12 |
| JPWO2021064428A5 true JPWO2021064428A5 (https=) | 2023-10-10 |
| JP2022551607A5 JP2022551607A5 (https=) | 2023-10-10 |
Family
ID=72811890
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520570A Pending JP2022551607A (ja) | 2019-10-03 | 2020-10-05 | ヘテロタンデム二環式ペプチド複合体 |
| JP2025101880A Active JP7770607B2 (ja) | 2019-10-03 | 2025-06-18 | ヘテロタンデム二環式ペプチド複合体 |
| JP2025185492A Pending JP2026027327A (ja) | 2019-10-03 | 2025-11-04 | ヘテロタンデム二環式ペプチド複合体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101880A Active JP7770607B2 (ja) | 2019-10-03 | 2025-06-18 | ヘテロタンデム二環式ペプチド複合体 |
| JP2025185492A Pending JP2026027327A (ja) | 2019-10-03 | 2025-11-04 | ヘテロタンデム二環式ペプチド複合体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11332500B2 (https=) |
| EP (3) | EP4592309A3 (https=) |
| JP (3) | JP2022551607A (https=) |
| CN (2) | CN119192401A (https=) |
| DK (1) | DK4464721T3 (https=) |
| ES (1) | ES3033517T3 (https=) |
| FI (1) | FI4464721T3 (https=) |
| HR (1) | HRP20250841T1 (https=) |
| HU (1) | HUE072242T2 (https=) |
| LT (1) | LT4464721T (https=) |
| PL (1) | PL4464721T3 (https=) |
| PT (1) | PT4464721T (https=) |
| RS (1) | RS67014B1 (https=) |
| SI (1) | SI4464721T1 (https=) |
| SM (1) | SMT202500247T1 (https=) |
| WO (1) | WO2021064428A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6882978B2 (ja) | 2014-10-29 | 2021-06-02 | バイスクルアールディー・リミテッド | Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド |
| JP7301757B2 (ja) | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
| CN111183147B (zh) | 2017-08-04 | 2024-07-05 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| JP2021514953A (ja) | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| JP7551500B2 (ja) | 2018-04-04 | 2024-09-17 | バイスクルテクス・リミテッド | ヘテロタンデム二環式ペプチド複合体 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| JP2022514618A (ja) | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| US12551567B2 (en) | 2018-12-21 | 2026-02-17 | Bicyclerd Limited | Bicyclic peptide ligands specific for PD-L1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| KR20220007098A (ko) | 2019-05-09 | 2022-01-18 | 바이사이클티엑스 리미티드 | Ox40에 특이적인 이환식 펩티드 리간드 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| ES3033517T3 (en) | 2019-10-03 | 2025-08-05 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes |
| KR20220146543A (ko) | 2020-02-27 | 2022-11-01 | 본스인코오포레이티드 | 수정된 에지를 갖는 mov 관련 디바이스 및 방법 |
| IL300248A (en) | 2020-08-03 | 2023-03-01 | Bicycletx Ltd | peptide-based linkers |
| US20250186539A2 (en) * | 2021-01-11 | 2025-06-12 | Bicycletx Limited | Methods for treating cancer |
| CN118215672A (zh) * | 2021-06-01 | 2024-06-18 | 南京明德新药研发有限公司 | 多肽偶联药物及其应用 |
| EP4704904A1 (en) * | 2023-05-04 | 2026-03-11 | Tambo, Inc. | Tetrazine-based targeting agents for in vivo delivery of a payload |
| CN121532408A (zh) * | 2023-06-23 | 2026-02-13 | 拜斯科技术开发有限公司 | 对nk细胞具有特异性的双环肽配体 |
| WO2025191096A1 (en) * | 2024-03-14 | 2025-09-18 | Bicycletx Limited | Bicyclic peptide |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4658014A (en) | 1985-12-20 | 1987-04-14 | Kempe Tomas G | Synthetic peptides with calcitonin-like activity |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| DK1844337T3 (da) | 2005-01-24 | 2013-09-30 | Pepscan Systems Bv | Bindingsforbindelser, immunogene forbindelser og peptidmimetika |
| JP5872751B2 (ja) * | 2006-02-06 | 2016-03-01 | バーナム インスティテュート フォー メディカル リサーチ | 腫瘍および損傷のターゲティングに関する方法および組成物 |
| AU2009211253B2 (en) * | 2008-02-05 | 2014-11-06 | Bicyclerd Limited | Methods and compositions |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| US20130130985A1 (en) | 2010-04-01 | 2013-05-23 | Paul Alewood | Oxytocin peptide analogues |
| WO2012057624A1 (en) | 2010-10-25 | 2012-05-03 | Pepscan Systems B.V. | Novel bicyclic peptide mimetics |
| AU2012320407B2 (en) | 2011-10-07 | 2017-04-20 | Bicyclerd Limited | Modulation of structured polypeptide specificity |
| GB201306623D0 (en) | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
| CN106794264B (zh) * | 2014-06-10 | 2021-03-23 | 3B制药有限公司 | 包含神经降压肽受体配体的缀合物及其用途 |
| JP6882978B2 (ja) | 2014-10-29 | 2021-06-02 | バイスクルアールディー・リミテッド | Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| AU2017252233A1 (en) * | 2016-04-22 | 2018-11-15 | Alligator Bioscience Ab | Novel bispecific polypeptides against CD137 |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| IL268836B2 (en) | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| CN111183147B (zh) | 2017-08-04 | 2024-07-05 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| JP2021514953A (ja) | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| JP7551500B2 (ja) | 2018-04-04 | 2024-09-17 | バイスクルテクス・リミテッド | ヘテロタンデム二環式ペプチド複合体 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| JP2022514618A (ja) | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| US20220184222A1 (en) | 2019-04-02 | 2022-06-16 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| KR20220007098A (ko) | 2019-05-09 | 2022-01-18 | 바이사이클티엑스 리미티드 | Ox40에 특이적인 이환식 펩티드 리간드 |
| TWI860386B (zh) * | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| WO2021028686A1 (en) * | 2019-08-13 | 2021-02-18 | Bicycletx Limited | Modified multimeric bicyclic peptide ligands |
| ES3033517T3 (en) | 2019-10-03 | 2025-08-05 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes |
-
2020
- 2020-10-05 ES ES24203287T patent/ES3033517T3/es active Active
- 2020-10-05 RS RS20250710A patent/RS67014B1/sr unknown
- 2020-10-05 HR HRP20250841TT patent/HRP20250841T1/hr unknown
- 2020-10-05 EP EP25175050.1A patent/EP4592309A3/en active Pending
- 2020-10-05 EP EP24203287.8A patent/EP4464721B1/en active Active
- 2020-10-05 LT LTEP24203287.8T patent/LT4464721T/lt unknown
- 2020-10-05 FI FIEP24203287.8T patent/FI4464721T3/fi active
- 2020-10-05 WO PCT/GB2020/052445 patent/WO2021064428A1/en not_active Ceased
- 2020-10-05 SM SM20250247T patent/SMT202500247T1/it unknown
- 2020-10-05 PL PL24203287.8T patent/PL4464721T3/pl unknown
- 2020-10-05 JP JP2022520570A patent/JP2022551607A/ja active Pending
- 2020-10-05 SI SI202030628T patent/SI4464721T1/sl unknown
- 2020-10-05 CN CN202411379106.7A patent/CN119192401A/zh active Pending
- 2020-10-05 PT PT242032878T patent/PT4464721T/pt unknown
- 2020-10-05 US US17/062,662 patent/US11332500B2/en active Active
- 2020-10-05 EP EP20789240.7A patent/EP4038096A1/en active Pending
- 2020-10-05 DK DK24203287.8T patent/DK4464721T3/da active
- 2020-10-05 CN CN202080069454.8A patent/CN114867753A/zh active Pending
- 2020-10-05 HU HUE24203287A patent/HUE072242T2/hu unknown
-
2022
- 2022-03-22 US US17/655,822 patent/US20220306694A1/en not_active Abandoned
-
2025
- 2025-06-18 JP JP2025101880A patent/JP7770607B2/ja active Active
- 2025-11-04 JP JP2025185492A patent/JP2026027327A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021064428A5 (https=) | ||
| AU2012326026B2 (en) | Peptidomimetic macrocyles | |
| JPWO2021019246A5 (https=) | ||
| AU2015320545C1 (en) | Peptidomimetic macrocycles and formulations thereof | |
| JPWO2020128526A5 (https=) | ||
| CN114555626A (zh) | 异串联双环肽复合物 | |
| CN114867753A (zh) | 异串联双环肽复合物 | |
| JP2025163134A (ja) | コンジュゲートされたヘプシジン模倣物 | |
| JP2014509859A5 (https=) | ||
| CA3189432A1 (en) | Conjugated hepcidin mimetics | |
| AR017120A1 (es) | Composiciones farmaceuticas que contienen proteina plasmatica. | |
| RS62392B1 (sr) | Tioetar peptidni antagonisti alfa4beta7 integrina | |
| CA3213688A1 (en) | Conjugated hepcidin mimetics | |
| EP2717902B1 (en) | Use of modified vasoactive intestinal peptides in the treatment of hypertension | |
| CN101983068B (zh) | N末端和c末端取代的人gh-rh拮抗类似物 | |
| JPWO2020120984A5 (https=) | ||
| JPH08505386A (ja) | 新規なペプチド | |
| JPWO2020225577A5 (https=) | ||
| JPWO2020120981A5 (https=) | ||
| JPWO2020120983A5 (https=) | ||
| AU2012267470A1 (en) | Therapeutic agents for regulating serum phosphorus | |
| BR112013031539A2 (pt) | agentes terapêuticos para regular fósforo sérico | |
| JP2002507886A (ja) | アンギオテンシン誘導体 | |
| KR20210068060A (ko) | 주사용 조성물 | |
| EP4408869A2 (en) | Compositions including tumor-binding gmcsf fusion proteins and methods of using the same to treat solid tumors |